{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:50:42Z","timestamp":1788922242916,"version":"build-2803163510"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","award":["RS-2023-00273553"],"award-info":[{"award-number":["RS-2023-00273553"]}]},{"name":"National Institute of Health","award":["K01AG068365"],"award-info":[{"award-number":["K01AG068365"]}]},{"name":"Agency for Healthcare Research and Quality, US Department of Health and Human Services","award":["R01 HS027623"],"award-info":[{"award-number":["R01 HS027623"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nondihydropyridine calcium channel blockers (CCBs), including diltiazem and verapamil, inhibit cytochrome P450 3A4 (CYP3A4), an enzyme involved in the metabolism of hydrocodone, the most commonly used opioid in the United States. This study evaluated whether concomitant use of hydrocodone with CYP3A4-inhibiting CCBs increases the risk of opioid overdose compared to use of hydrocodone with amlodipine, a CCB that does not inhibit CYP3A4. Using 3 US databases (2000-2021), two cohorts were identified: (1) hydrocodone initiation while on CCB; and (2) CCB initiation while on hydrocodone. The outcome was hospitalization or emergency department visits for opioid overdose. Propensity score matching weights were applied to balance confounders, and Cox regression estimated HRs, pooled using random-effects meta-analysis. In hydrocodone initiation cohort (mean age 61.2\u00a0years; 53.8% female), weighted incidence rates were 2.8 and 2.6 per 1000 person-years, with a weighted HR of 1.07 (95% CI, 0.90-1.29). In CCB initiation cohort (mean age 55.2\u00a0years; 59.9% female), weighted incidence rates were 6.5 and 6.0, yielding an HR of 1.08 (95% CI, 0.88-1.32). The pooled HR was 1.07 (95% CI, 0.94-1.23). Concomitant use of hydrocodone with CYP3A4-inhibiting CCBs was not associated with an increased risk of opioid overdose relative to amlodipine.<\/jats:p>\n                  <jats:p>Trial registration: Real World Evidence Registry- https:\/\/osf.io\/ybdt5<\/jats:p>","DOI":"10.1093\/aje\/kwaf198","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T08:33:57Z","timestamp":1757061237000},"page":"3609-3619","source":"Crossref","is-referenced-by-count":4,"title":["Risk of opioid overdose associated with concurrent use of hydrocodone and CYP3A4-inhibiting calcium channel blockers: a population-based cohort study"],"prefix":"10.1093","volume":"194","author":[{"given":"Sungho","family":"Bea","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]},{"name":"School of Pharmacy, Sungkyunkwan University , Suwon ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Andrew","family":"Basham","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba H","family":"Edrees","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5805-8430","authenticated-orcid":false,"given":"Krista F","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seanna M","family":"Vine","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Glynn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine , Stanford, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-5412","authenticated-orcid":false,"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"issue":"7","key":"2025120218113777600_ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22303","article-title":"Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 pandemic, 2011-2021","volume":"6","author":"Gomes","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2025120218113777600_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.0217","article-title":"The burden of opioid-related mortality in the United States","volume":"1","author":"Gomes","year":"2018","journal-title":"JAMA Netw Open."},{"issue":"8","key":"2025120218113777600_ref3","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.2105\/AJPH.2014.301966","article-title":"Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review","volume":"104","author":"King","year":"2014","journal-title":"Am J Public Health."},{"key":"2025120218113777600_ref4","author":"CDC National Center for Health Statistics"},{"key":"2025120218113777600_ref5","author":"CDC National Center for Health Statistics"},{"key":"2025120218113777600_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103888","article-title":"U.S. state policies on opioid prescribing during the peak of the prescription opioid crisis: associations with opioid overdose mortality","volume":"110","author":"Buonora","year":"2022","journal-title":"Int J Drug Policy."},{"issue":"10","key":"2025120218113777600_ref7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/add.13741","article-title":"Do more robust prescription drug monitoring programs reduce prescription opioid overdose?","volume":"112","author":"Pardo","year":"2017","journal-title":"Addiction."},{"issue":"3","key":"2025120218113777600_ref8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/08897077.2019.1709605","article-title":"Regional and temporal effects of naloxone access laws on opioid overdose mortality","volume":"42","author":"Cataife","year":"2021","journal-title":"Subst Abus."},{"key":"2025120218113777600_ref9","author":"Office of Disease Prevention and Health Promotion. Reduce overdose deaths involving natural and semisynthetic opioids\u2014IVP 21"},{"key":"2025120218113777600_ref10","author":"CDC NCfHS"},{"issue":"6 Suppl","key":"2025120218113777600_ref11","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpainsymman.2012.08.013","article-title":"Opioid therapies and cytochrome p450 interactions","volume":"44","author":"Gudin","year":"2012","journal-title":"J Pain Symptom Manage."},{"issue":"1","key":"2025120218113777600_ref12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict Jan-Feb."},{"issue":"Suppl 11","key":"2025120218113777600_ref13","first-page":"S276","article-title":"Opioid pharmacokinetic drug-drug interactions","volume":"17","author":"Overholser","year":"2011","journal-title":"Am J Manag Care."},{"issue":"12","key":"2025120218113777600_ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.31647","article-title":"Association of gabapentinoids with the risk of opioid-related adverse events in surgical patients in the United States","volume":"3","author":"Bykov","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2025120218113777600_ref15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/cpt.3479","article-title":"Risk of opioid overdose associated with concomitant use of methadone and statins","volume":"117","author":"Chen","year":"2025","journal-title":"Clin Pharmacol Ther."},{"issue":"13","key":"2025120218113777600_ref16","doi-asserted-by":"publisher","first-page":"e1432","DOI":"10.1212\/WNL.0000000000200904","article-title":"Comparative risk of opioid overdose with concomitant use of prescription opioids and skeletal muscle relaxants","volume":"99","author":"Khan","year":"2022","journal-title":"Neurology."},{"issue":"8","key":"2025120218113777600_ref17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.7326\/M23-3109","article-title":"Clinical and adverse outcomes associated with concomitant use of CYP2D6-metabolized opioids with antidepressants in older nursing home residents: a target trial emulation study","volume":"177","author":"Wei","year":"2024","journal-title":"Ann Intern Med."},{"issue":"2","key":"2025120218113777600_ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0194","article-title":"Risk of opioid overdose associated with concomitant use of oxycodone and selective serotonin reuptake inhibitors","volume":"5","author":"Yunusa","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"4","key":"2025120218113777600_ref19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cpt.2314","article-title":"Coprescription of opioids with other medications and risk of opioid overdose","volume":"110","author":"Khan","year":"2021","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"2025120218113777600_ref20","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/cpt.2717","article-title":"Identifying clinically relevant drug-drug interactions with methadone and buprenorphine: a translational approach to signal detection","volume":"112","author":"Miano","year":"2022","journal-title":"Clin Pharmacol Ther."},{"issue":"13","key":"2025120218113777600_ref21","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1161\/CIR.0000000000000549","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation."},{"issue":"6","key":"2025120218113777600_ref22","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens."},{"key":"2025120218113777600_ref23","author":"CDC National Center for Injury Prevention and Control","year":"2018"},{"issue":"4","key":"2025120218113777600_ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38007","article-title":"Opioid agents and cardiac arrhythmia: a literature review","volume":"15","author":"Golibkhon","year":"2023","journal-title":"Cureus."},{"issue":"1","key":"2025120218113777600_ref25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12916-021-02192-1","article-title":"The impact of high-risk medications on mortality risk among older adults with polypharmacy: evidence from the English longitudinal study of ageing","volume":"19","author":"Huang","year":"2021","journal-title":"BMC Med."},{"issue":"5","key":"2025120218113777600_ref26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bcp.12541","article-title":"Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor","volume":"79","author":"Frost","year":"2015","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"2025120218113777600_ref27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.1365-2125.2005.02343.x","article-title":"Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein","volume":"59","author":"Pinto","year":"2005","journal-title":"Br J Clin Pharmacol."},{"issue":"5","key":"2025120218113777600_ref28","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1124\/dmd.104.001834","article-title":"Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil","volume":"33","author":"Wang","year":"2005","journal-title":"Drug Metab Dispos."},{"issue":"4","key":"2025120218113777600_ref29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab."},{"issue":"2","key":"2025120218113777600_ref30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1124\/jpet.113.207548","article-title":"In vivo activity of norhydrocodone: an active metabolite of hydrocodone","volume":"347","author":"Navani","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"issue":"7","key":"2025120218113777600_ref31","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jamainternmed.2020.0989","article-title":"Trends in utilization of prescribed controlled substances in US commercially insured adults, 2004-2019","volume":"180","author":"Bykov","year":"2020","journal-title":"JAMA Intern Med."},{"issue":"2","key":"2025120218113777600_ref32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-015-0378-5","article-title":"Appropriate polypharmacy and medicine safety: when many is not too many","volume":"39","author":"Cadogan","year":"2016","journal-title":"Drug Saf."},{"issue":"11-12","key":"2025120218113777600_ref33","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s002280050706","article-title":"Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions","volume":"55","author":"Katoh","year":"2000","journal-title":"Eur J Clin Pharmacol."},{"issue":"1","key":"2025120218113777600_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70088","article-title":"Core concepts in pharmacoepidemiology: evaluation of drug-drug interactions in pharmacoepidemiologic research","volume":"34","author":"Chen","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"2025120218113777600_ref35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/cpt.277","article-title":"Pharmacoepidemiologic methods for studying the health effects of drug-drug interactions","volume":"99","author":"Hennessy","year":"2016","journal-title":"Clin Pharmacol Ther."},{"issue":"8","key":"2025120218113777600_ref36","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol."},{"issue":"17","key":"2025120218113777600_ref37","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/archinternmed.2011.284","article-title":"Quality of care in the US territories","volume":"171","author":"Nunez-Smith","year":"2011","journal-title":"Arch Intern Med."},{"issue":"10","key":"2025120218113777600_ref38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1124\/dmd.32.10.1083","article-title":"Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs","volume":"32","author":"McConn","year":"2004","journal-title":"Drug Metab Dispos."},{"issue":"3","key":"2025120218113777600_ref39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"Eur J Pharm Sci."},{"issue":"4","key":"2025120218113777600_ref40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/acem.13121","article-title":"Performance measures of diagnostic codes for detecting opioid overdose in the emergency department","volume":"24","author":"Rowe","year":"2017","journal-title":"Acad Emerg Med."},{"issue":"2","key":"2025120218113777600_ref41","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/0033354920904087","article-title":"ICD-10-CM-based definitions for emergency department opioid poisoning surveillance: electronic health record case confirmation study","volume":"135","author":"Slavova","year":"2020","journal-title":"Public Health Rep."},{"issue":"3","key":"2025120218113777600_ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain - United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep."},{"issue":"7","key":"2025120218113777600_ref43","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol."},{"issue":"7","key":"2025120218113777600_ref44","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/gerona\/glx229","article-title":"Measuring frailty in Medicare data: development and validation of a claims-based frailty index","volume":"73","author":"Kim","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"2","key":"2025120218113777600_ref45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat."},{"issue":"3","key":"2025120218113777600_ref46","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology."},{"issue":"2","key":"2025120218113777600_ref47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods."},{"issue":"4","key":"2025120218113777600_ref48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1254\/jphs.fp0040252","article-title":"Involvement of peripheral mechanism in the verapamil-induced potentiation of morphine analgesia in mice","volume":"95","author":"Shimizu","year":"2004","journal-title":"J Pharmacol Sci."},{"issue":"1","key":"2025120218113777600_ref49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0022-3565(25)25009-1","article-title":"Interactions between verapamil and morphine on physiological parameters in rats","volume":"238","author":"Szikszay","year":"1986","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"2025120218113777600_ref50","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S0022-3565(25)39589-3","article-title":"Effects of verapamil on morphine-induced euphoria, analgesia and respiratory depression in humans","volume":"267","author":"Vaupel","year":"1993","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"2025120218113777600_ref51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1213\/00000539-199709000-00026","article-title":"The influence of three L-type calcium channel blockers on morphine effects in healthy volunteers","volume":"85","author":"Hasegawa","year":"1997","journal-title":"Anesth Analg."},{"issue":"2","key":"2025120218113777600_ref52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0090-9556(24)15118-5","article-title":"Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A","volume":"28","author":"Ma","year":"2000","journal-title":"Drug Metab Dispos."},{"issue":"3","key":"2025120218113777600_ref53","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cjco.2021.11.002","article-title":"Amiodarone, verapamil, or diltiazem use with direct oral anticoagulants and the risk of hemorrhage in older adults","volume":"4","author":"Hill","year":"2022","journal-title":"CJC Open."},{"issue":"12","key":"2025120218113777600_ref54","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40266-021-00893-z","article-title":"Problematic opioid use among older adults: epidemiology, adverse outcomes and treatment considerations","volume":"38","author":"Dufort","year":"2021","journal-title":"Drugs Aging."},{"issue":"9","key":"2025120218113777600_ref55","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ejim.2014.10.001","article-title":"Understanding adverse drug reactions in older adults through drug-drug interactions","volume":"25","author":"Marengoni","year":"2014","journal-title":"Eur J Intern Med."},{"issue":"1","key":"2025120218113777600_ref56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227966","article-title":"Socioeconomic risk factors for fatal opioid overdoses in the United States: findings from the mortality disparities in American communities study (MDAC)","volume":"15","author":"Altekruse","year":"2020","journal-title":"PloS One."},{"issue":"4","key":"2025120218113777600_ref57","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dom.13184","article-title":"Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records","volume":"20","author":"Patorno","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"2025120218113777600_ref58","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2025120218113777600_ref59","volume-title":"Modern Epidemiology","author":"Rothman","year":"2008","edition":"3rd"},{"issue":"12","key":"2025120218113777600_ref60","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/jamia\/ocz094","article-title":"A primer on quantitative bias analysis with positive predictive values in research using electronic health data","volume":"26","author":"Newcomer","year":"2019","journal-title":"J Am Med Inform Assoc."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwaf198\/64213072\/kwaf198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/12\/3609\/64213072\/kwaf198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/194\/12\/3609\/64213072\/kwaf198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T23:11:42Z","timestamp":1764717102000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/194\/12\/3609\/8248252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,5]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwaf198","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,5]]}}}